本文選題：髓細(xì)胞肉瘤 + 臨床特點(diǎn)　； 參考：《腫瘤防治研究》2017年06期

【摘要】：目的探討髓細(xì)胞肉瘤的臨床特點(diǎn)及其預(yù)后。方法回顧性分析2001年至2014年北京大學(xué)第三醫(yī)院血液科收治10例髓細(xì)胞肉瘤患者的資料,對其臨床特點(diǎn)及預(yù)后進(jìn)行總結(jié)。結(jié)果 10例患者中女性6例,男性4例,中位發(fā)病年齡為40.5歲,受累部位包括皮膚、乳腺、淋巴結(jié)、胸骨周圍、宮頸、支氣管,均接受化療為主的治療,5例死亡。中位生存期為12月,自診斷髓細(xì)胞肉瘤之日算起,最長存活240月。結(jié)論髓細(xì)胞肉瘤是一種罕見的局限性腫瘤,系統(tǒng)性化療應(yīng)在疾病確診后盡快使用,造血干細(xì)胞移植可改善不良預(yù)后。
[Abstract]:Objective to investigate the clinical features and prognosis of myelocytic sarcoma. Methods the data of 10 cases of myelocytic sarcoma treated in hematology department of the third Hospital of Peking University from 2001 to 2014 were analyzed retrospectively and their clinical characteristics and prognosis were summarized. Results among the 10 patients, 6 were female and 4 were male. The median age of onset was 40.5 years old. The affected areas included skin, mammary gland, lymph nodes, sternum, cervix and bronchus. The median survival time was 12 months, and the longest survival time was 240 months from the date of diagnosis of medullary sarcoma. Conclusion Myelocytic sarcoma is a rare localized tumor, systemic chemotherapy should be used as soon as possible after the diagnosis of the disease, hematopoietic stem cell transplantation can improve the poor prognosis.
【作者單位】： 北京大學(xué)第三醫(yī)院血液科;
【基金】：北京市自然科學(xué)基金(7132183)
【分類號】：R733

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 陳厚初;吳校歧;石人優(yōu);柏乃慶;丁訓(xùn)杰;丁鉞;陳榮珍;楊家寬;丁志圣;程文英;羅偉華;張鴻壽;;骨髓細(xì)胞低溫(4℃)保存的實驗研究和臨床初步應(yīng)用[J];上海醫(yī)學(xué);1983年06期

2 朱士紅;王永志;朱理平;潘麗;山德生;;急性混合細(xì)胞白血病2例[J];現(xiàn)代診斷與治療;2009年02期

3 陳震章;張啟國;歐陽建;孫雪梅;范洵楠;;皮下髓細(xì)胞肉瘤1例[J];臨床血液學(xué)雜志;2006年05期

4 曾惠;胡俊斌;郭曉s，

本文編號：1949553